Ticlopidine and clopidogrel in secondary stroke prevention

Cerebrovascular Diseases

Volumn 7, Issue , 1997, Pages 17-23

  Bousser, M G ^a   Roberts, R S ^b   Gent, M ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; CLOPIDOGREL; FIBRINOGEN; THROMBOCYTE RECEPTOR; THROMBOXANE A2; TICLOPIDINE;

BRAIN HEMORRHAGE; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; NEUTROPENIA; PEPTIC ULCER; PRIORITY JOURNAL; RASH; SECONDARY PREVENTION; STROKE; THROMBOCYTE AGGREGATION;

EID: 0030729652     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000108276     Document Type: Article

References (16)

1. Panak E. Maffrand JP, Picard-Frairc C, Vallcc E, Blanchard J. Roncucci R: Ticlopidine: A promise for the prevention and treatment of thrombosis and its complications. Haemostasis 1953; 13(suppl 1):1-54.
2. McTavish D, Faulds D, Goa KL: Ticlopidine. An updalcd review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990;40:238-259.
3. Herbert JM. Frcehel D. Vallee E: Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993:11:180-198.
4. Herbert JM, Tissinier A. Dcfrcyn G, Maffrand JP: Inhibitory effect of clopidogrcl on platelet adhesion and intimal proliferation following arterial injury' in rabbits. Arteriosclerosis Thromb 1993;13:1171-1179.
5. 3H)-2-methylthio ADP to rat platelets: Effect of clopidogrcl and ticlopidine. J Pharmacol ExpTher 1994:269:772-777.
6. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrcl versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996:348:1329-1339.
7. Gent M, Blakely JA, Easton JD, Ellis DJ, Ha-chinski VC, Harbison JW, Panak E, Roberts RS, Tech M, Sicurclla J, Turpie AGG, and the CATS group: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Stroke 1988;19:1203-1210.
8. Gent M, Blakely JA, Easton JD, Ellis DJ, Ha-chinski VC, Harbison JW, Panak E, Roberts RS, Sicurclla J, Alexander GG, Turpie AGG, and the CATS group: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;1: 1215-1220.
9. Hass WK. Easton DJ. Adams HP Jr. Pryse-Phillips W, Molony BA, Anderson S. Kamm B: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
10. The Canadian Cooperative Study Group: A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Eng J Med 1978:299: 53-59.
11. Bousscr MG, Eschwcgc F, Hagucnau M. Lcfau-connicr JM. Thibult N. Touboul D, Touboul PJ: ‘AICL.V controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. Stroke 1953:14:5-14.
12. UK-TIA Study Group: United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: Interim results. BMJ 1988:296:310-320.
13. Antiplaielet Trialists Collaboration: Secondary prevention of vascular disease by prolonged antiplaielet treatment. BMJ 1988:296:320-331.
14. van Gijn J: Ticlopidine. trials and torture. Stroke 1994.25.1097-1098.
15. Warlow C: Ticlopidine, a new antithrombotic drug: But is it better than aspirin for long term use? J Neurol Neurosurg Psvchiatrv 1990:53: 185-187.
16. Bom GVR. Collins R: Aspirin versus clopidogrcl: The wrong question? Lancet 1997,349. 806-807.